EGFR and neoplasm: Similarly, luminespib (Hsp90 inhibitor) (Fig. 5b) and sapitinib (Erbb inhibitor) (Fig. 5c) are predicted to have high tumor specificity largely for LUSC with high tumor-to-normal sensitivity for the tissue type.